- Home
- BDSX
BDSX
Biodesix Inc.
as 11-21-2024 4:00pm EST
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | LOUISVILLE |
| Market Cap: | 200.0M | IPO Year: | 2020 |
| Target Price: | $3.08 | AVG Volume (30 days): | 732.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.11 - $2.21 | Next Earning Date: | 11-01-2024 |
| Revenue: | $65,562,000 | Revenue Growth: | 48.92% |
| Revenue Growth (this year): | 46.97% | Revenue Growth (next year): | 30.43% |
Stock Insider Trading Activity of Biodesix Inc. (BDSX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Vazquez Chris | BDSX | Chief Accounting Officer | Nov 8 '24 | Sell | $1.40 | 203 | $283.32 | 11,685 | |
| Cowie Robin Harper | BDSX | CFO, Sec'y & Treasurer | Nov 8 '24 | Sell | $1.40 | 971 | $1,355.23 | 203,807 | |
| O'Kane Kieran | BDSX | Chief Commercial Officer | Nov 8 '24 | Sell | $1.40 | 462 | $644.81 | 97,672 | |
| Strobeck Matthew | BDSX | Director | Nov 5 '24 | Buy | $1.40 | 40,000 | $55,916.00 | 89,673 | |
| SCHULER JACK W | BDSX | Director10% Owner | Nov 5 '24 | Buy | $1.36 | 100,253 | $136,584.69 | 30,894,935 | |
| PATIENCE JOHN | BDSX | Director | Nov 5 '24 | Buy | $1.38 | 75,000 | $103,710.00 | 2,153,298 | |
| MASSARANY HANY | BDSX | Director | Nov 5 '24 | Buy | $1.37 | 22,500 | $30,865.50 | 53,364 |
Latest Biodesix Inc. News
BDSX Breaking Stock News: Dive into BDSX Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Simply Wall St.
19 days ago
Biodesix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
GuruFocus.com
20 days ago
Biodesix Inc (BDSX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...
MT Newswires
21 days ago
Biodesix Stockholders to Sell 62.2 Million Shares; Files $250 Million Mixed-Shelf Offering
Zacks
21 days ago
Biodesix, Inc. (BDSX) Reports Q3 Loss, Misses Revenue Estimates
GlobeNewswire
21 days ago
Biodesix Announces Third Quarter 2024 Results and Highlights
GuruFocus.com
22 days ago
What To Expect From Biodesix Inc (BDSX) Q3 2024 Earnings
Simply Wall St.
22 days ago
With 47% ownership, Biodesix, Inc. (NASDAQ:BDSX) insiders have a lot riding on the company's future
Compare BDSX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BDSX Biodesix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.